Eledon shares drop as tegoprubart misses the main goal in Phase 2 kidney transplant trial, though safety signals and kidney function data remain encouraging.
Eledon shares drop as tegoprubart misses the main goal in Phase 2 kidney transplant trial, though safety signals and kidney function data remain encouraging.
Copyright © Louis Velazquez. All Rights Reserved.